Best er for back pain trial#

These items are provided solely for informational purposes and are not intended as a substitute for consultation with a medical professional. As a result, routine imaging of the low back should be avoided in order to reduce ionizing radiation exposure and unnecessary cost. The vast majority of cases of back pain in the ED are related to muscle strain or inflammation. Diagnostic imaging does not accurately identify the cause of most low back pain and does not improve the time to recovery. When a patient has symptoms or physical findings of a serious or progressive neurological condition, or is suspected of having a serious underlying condition such as cancer or a spinal infection, imaging may be appropriate and may include plain X-rays or advanced imaging (e.g., MRI or CT scan). Most of the time, such pain is caused by conditions such as a muscle strain or a bulging disc that cannot be identified on an X-ray or CT scan. Low back pain without trauma is a common presenting complaint in the emergency department (ED). OPANA ER may provide clinicians with a new treatment option for patients experiencing suboptimal analgesic responses or poor tolerability with other opioids.View all recommendations from this societyДЄvoid lumbar spine imaging in the emergency department for adults with non-traumatic back pain unless the patient has severe or progressive neurologic deficits or is suspected of having a serious underlying condition (such as vertebral infection, cauda equina syndrome, or cancer with bony metastasis).

Best er for back pain trial#

In a 12-week, double-blind, randomized, placebo-controlled trial in opioid-experienced patients with chronic, moderate to severe LBP, OPANA ER provided efficacious, long-term analgesia and was generally well-tolerated. Fifty-seven percent of opioid-experienced patients with chronic, moderate to severe LBP achieved a stable dose of OPANA ER that was efficacious and generally well-tolerated for up to 12 weeks. Opioid-related adverse events included constipation (6%), somnolence (3%), and nausea (3%). Discontinuations as a result of adverse events were similar between groups, 10% with placebo and 11% with OPANA ER. During double-blind treatment, placebo patients were approximately 8-fold more likely than OPANA ER patients to discontinue because of lack of efficacy (P <.

Pain intensity increased significantly more for patients randomized to placebo than for patients who continued their stabilized dose of OPANA ER the increase from baseline (at randomization) to final visit was 31.6 mm for placebo versus 8.7 mm with OPANA ER (P <. Stabilized patients (n = 143) were randomized to placebo or their stabilized dose of OPANA ER every 12 hours for a 12-week double-blind period. Patients continued slow titration, with 56% stabilized within 1 month to a dose of OPANA ER that reduced average pain to <40 mm on a visual analog scale with good tolerability.

Opioid-experienced (N = 250) patients with chronic, moderate to severe low back pain (LBP) were converted from their prestudy opioid(s) to an approximately equianalgesic dose of OPANA ER (oxymorphone extended release).